Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The average one-year price target for ProMIS Neurosciences (NasdaqCM:PMN) has been revised to $35.06 / share. This is a decrease of 57.76% from the prior estimate of $83.00 dated February 21, 2026.

Biogen BIIB initiated dosing in a global, late-stage study of its investigational candidate, felzartamab, for treating adult patients with primary membranous nephropathy (PMN). Top-line data readout ...

ProMIS Neurosciences Inc. PMN shares skyrocketed Monday after the company presented preclinical data supporting the potential therapeutic advantage of its lead candidate for Alzheimer's disease (AD), ...

Studies have shown that PMN from adults and neonates exhibit heterogeneity of function and 31D8 MAb binding. The heterogenity of 31D8 binding correlates with PMN motile heterogeneity. MOI MAb binds to ...

View ProMIS Neurosciences Inc. PMN stock quote prices, financial information, real-time forecasts, and company news from CNN.